When people ask about stopping Eliquis before colonoscopy, the answer depends partly on what the endoscopist plans to do. A diagnostic examination, sometimes with a small biopsy, is generally considered lower risk for bleeding than removing a polyp. Because a polyp may be found during the exam, confirm the plan with your endoscopy team before changing any dose of Eliquis (apixaban), Xarelto (rivaroxaban), dabigatran or edoxaban.
Stopping Eliquis Before Colonoscopy: The Procedure Matters
The joint British Society of Gastroenterology and European Society of Gastrointestinal Endoscopy (BSG/ESGE) guideline classifies diagnostic endoscopy, including biopsy, as low risk. Polypectomy is classed as high risk because removing tissue can cause bleeding during or after the procedure. Larger or more complex removals may need additional planning.
This distinction matters if a colonoscopy could shift from looking to treating. Ask whether the endoscopist expects to remove polyps if found, or might instead document them and arrange a separate procedure. Your team can then give you a plan that accounts for the likely procedure rather than treating every colonoscopy as identical.
How Guidance Sets Pause And Restart Timing
In its 2021 update, a guideline committee representing the UK’s BSG and the European Society of Gastrointestinal Endoscopy advised that people having a low-risk procedure omit the morning DOAC dose on the day of the procedure. For a high-risk procedure such as polypectomy, it advised taking the last dose three days before. The guidance generally places restarting a DOAC up to two or three days after a high-risk procedure, depending on bleeding and clotting risks.
The timing has changed across guideline versions: the 2016 BSG/ESGE guideline advised a last dose at least 48 hours before a high-risk procedure, with a longer interval for some people taking dabigatran. The updated 2021 guidance uses three days for high-risk procedures. These are guideline schedules, not instructions for you to follow on your own. Guidance and local protocols can differ by country and care setting, so ask your team for the exact date and time of your last dose and when to restart.
Restarting too soon after tissue removal may increase bleeding risk; waiting longer than needed leaves you without your usual protection against clots for more time. The endoscopist should tell you when to resume, taking account of what was done and whether bleeding was controlled.
Why Kidney Function And Clot Risk Matter
Kidney function can affect how long a DOAC stays active. This is especially important with dabigatran: the 2021 BSG/ESGE guideline advises a longer pause—five days before a high-risk procedure—when kidney function is in the 30–50 mL/min range (measured as creatinine clearance or estimated glomerular filtration rate). That interval should not be applied to every DOAC or every person. Tell the team about kidney disease or recent changes in kidney function; they can check which measure and timing apply to your medicine.
The reason you take a DOAC and your history also matter. For example, a recent blood clot, particularly within the past three months, can make interruption more concerning. The BSG/ESGE guideline says to consider delaying a high-risk elective procedure until after the first three months of treatment when appropriate. If your clot was recent or your circumstances are unusual, your prescriber and endoscopy team may need to coordinate the plan.
Why Bridging Is Usually Not Needed
“Bridging” means using an injectable anticoagulant, often heparin, while an oral anticoagulant is paused. For DOACs, routine bridging is generally not recommended. These medicines have a relatively short duration of action, and the BSG/ESGE guidance says bridging is not appropriate for most people taking a DOAC for a previous venous clot. An injection is not a substitute to arrange yourself; it can add bleeding risk. Your clinicians can assess exceptional situations.
Get A Written Plan Before Bowel Preparation
Before starting bowel preparation, make sure you know:
- Whether the procedure is diagnostic only or may include polyp removal.
- Exactly when to take your last dose and when to restart it.
- Whether your kidney function, DOAC type or recent clot history changes the schedule.
- Who to contact if your instructions are missing or conflict with your usual prescription.
Do not stop, skip or restart doses based on a general timetable or search result. If you have not received clear instructions, contact your endoscopy service or the clinician who prescribes your DOAC before making a change.
